Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced its participation in two upcoming investor conferences. The company will attend the Third Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York City, where management will meet with investors. Additionally, CEO Dr. Adi Mor will participate in a fireside chat at the Maxim Healthcare Virtual Summit on October 16, 2024, at 9:00 am ET.
The ROTH conference will feature one-on-one meetings with investors, while the Maxim Healthcare Summit will include a virtual fireside chat. A recording of the Maxim Summit fireside chat will be made available on Chemomab's investor relations website after the event. Both conferences are invitation-only events.
Chemomab Therapeutics (Nasdaq: CMMB), un'azienda biotecnologica in fase clinica focalizzata sulle malattie fibro-infiammatorie, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà al Terzo Annuale ROTH Healthcare Opportunities Conference il 9 ottobre 2024, a New York City, dove la direzione incontrerà gli investitori. Inoltre, il CEO Dr. Adi Mor parteciperà a una chiacchierata informale al Maxim Healthcare Virtual Summit il 16 ottobre 2024, alle 9:00 ET.
La conferenza ROTH prevede incontri one-to-one con gli investitori, mentre il Maxim Healthcare Summit includerà una chiacchierata informale virtuale. Una registrazione della chiacchierata informale del Maxim Summit sarà resa disponibile sul sito web delle relazioni con gli investitori di Chemomab dopo l'evento. Entrambi gli eventi sono su invito.
Chemomab Therapeutics (Nasdaq: CMMB), una empresa biotecnológica en etapa clínica centrada en enfermedades fibro-inflamatorias, ha anunciado su participación en dos próximas conferencias para inversores. La empresa asistirá a la Tercera Conferencia Anual de Oportunidades en Salud ROTH el 9 de octubre de 2024, en Nueva York, donde la dirección se reunirá con inversores. Además, el CEO Dr. Adi Mor participará en un chat informal en el Maxim Healthcare Virtual Summit el 16 de octubre de 2024, a las 9:00 a.m. ET.
La conferencia ROTH contará con reuniones uno a uno con los inversores, mientras que el Maxim Healthcare Summit incluirá un chat informal virtual. Se pondrá a disposición una grabación del chat informal del Maxim Summit en el sitio web de relaciones con inversores de Chemomab después del evento. Ambas conferencias son eventos solo por invitación.
Chemomab Therapeutics (Nasdaq: CMMB), 섬유염증성 질환에 집중하는 임상 단계의 생명공학 회사,는 두 개의 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 2024년 10월 9일 뉴욕에서 열리는 제3회 연례 ROTH 헬스케어 기회 회의에 참석하여 경영진이 투자자와 만날 예정입니다. 또한 CEO Dr. Adi Mor는 2024년 10월 16일 오전 9시 ET에 Maxim Healthcare Virtual Summit에서 진행되는 파이어사이드 챗에 참여할 것입니다.
ROTH 회의는 투자자와의 일대일 미팅을 특징으로 하며, Maxim Healthcare Summit은 가상 파이어사이드 챗을 포함합니다. Maxim Summit의 파이어사이드 챗 기록은 행사 후 Chemomab의 투자자 관계 웹사이트에서 제공될 예정입니다. 두 회의 모두 초청 전용 행사입니다.
Chemomab Therapeutics (Nasdaq: CMMB), une entreprise de biotechnologie en phase clinique axée sur les maladies fibro-inflammatoires, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise assistera à la Troisième Conférence Annuelle sur les Opportunités en Santé ROTH le 9 octobre 2024, à New York, où la direction rencontrera des investisseurs. De plus, le CEO Dr. Adi Mor participera à une discussion informelle lors du Sommet Virtuel Maxim Healthcare le 16 octobre 2024, à 9h00 ET.
La conférence ROTH comportera des réunions individuelles avec des investisseurs, tandis que le Sommet Maxim Healthcare inclura une discussion informelle virtuelle. Un enregistrement de la discussion informelle du Maxim Summit sera disponible sur le site web des relations investisseurs de Chemomab après l'événement. Les deux conférences sont sur invitation uniquement.
Chemomab Therapeutics (Nasdaq: CMMB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf fibro-inflammatorische Erkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 9. Oktober 2024 an der Dritten jährlichen ROTH Healthcare Opportunities Conference in New York City teilnehmen, wo das Management mit Investoren zusammentreffen wird. Darüber hinaus wird CEO Dr. Adi Mor am 16. Oktober 2024 um 9:00 Uhr ET an einem Fireside-Chat beim Maxim Healthcare Virtual Summit teilnehmen.
Die ROTH-Konferenz wird Einzelgespräche mit Investoren beinhalten, während der Maxim Healthcare Summit einen virtuellen Fireside-Chat umfasst. Eine Aufzeichnung des Fireside-Chats des Maxim Summit wird nach der Veranstaltung auf der Investor-Relations-Website von Chemomab verfügbar sein. Beide Konferenzen sind ausschließlich auf Einladung.
- None.
- None.
TEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that senior management will participate in two upcoming investor conferences.
Chemomab management will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York City on October 9, 2024, and Chemomab co-founder and Chief Executive Officer Dr. Adi Mor will participate in a fireside chat with senior biotechnology analyst Michael Okunewitch at the Maxim Healthcare Virtual Summit on October 16, 2024 at 9:00 am ET.
These conferences are by invitation only. A recording of the Maxim Healthcare Summit fireside chat will be available via a link on the Chemomab investor relations website after the conference completes.
Chemomab Participation in Third Annual ROTH Healthcare Opportunities Conference
| Date: | October 9, 2024 |
| Time: | 9:00 am ET - 5:00 pm ET |
| Venue: | Metropolitan Club, New York City |
| Format: | One-on-one meetings with investors |
| Information: | https://www.meetmax.com/sched/event_111103/conference_home.html |
Chemomab Participation in 2024 Maxim Healthcare Virtual Summit
| Date: | October 16, 2024 |
| Time: | 9:00 am ET |
| Venue: | Virtual |
| Format: | Fireside chat with CEO Dr. Adi Mor |
| Link: | Recording will be available at investors.chemomab.com post-conference. |
| Information: | https://m-vest.com/events/healthcare-10152024 |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a dual activity monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two upcoming milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When is Chemomab Therapeutics (CMMB) participating in the ROTH Healthcare Opportunities Conference?
What type of event is Chemomab Therapeutics (CMMB) attending at the Maxim Healthcare Virtual Summit?
Will there be a recording available of Chemomab's (CMMB) presentation at the Maxim Healthcare Virtual Summit?
What is the format of Chemomab's (CMMB) participation in the ROTH Healthcare Opportunities Conference?
